International Stem Cell Corporation (OTCBB:ISCO),
www.internationalstemcell.com,
announced today the following near-term events as part of its ongoing
efforts to increase scientific awareness of the Company, its proprietary
Parthenogenic Stem Cell Lines, and their potential uses in research and
therapy:
-
Kenneth Aldrich, Chairman of ISCO, will participate in two panel
discussions regarding biotech funding and exit strategies at the "Cell
and Gene Therapy Forum 2010" in Washington DC on January 25 and 26,
2010 (www.phacilitate.co.uk/pages/cgtherapy/).
-
Brian Lundstrom, President of ISCO, will present the company and its
Asian partnering opportunities in cell culture products, cornea
transplantation and universal stem cells at "BIO Asia Partnering" in
Tokyo on January 26, 2010. (http://bioasia.bio.org/opencms/bioasia/2010/).
-
Mr. Aldrich will provide a webinar on ISCO's strategy and 2010 plans
on February 5, 2010. Participation details will be available on the
company's web site before the event and the web cast will be posted on
the site afterwards.
ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California-based biotechnology
company focused on therapeutic and research products. ISCO's core
technology, parthenogenesis, results in creation of pluripotent
human stem cells from unfertilized oocytes (eggs). ISCO scientists have
created the first parthenogenic, homozygous stem cell line that
can be a source of therapeutic cells with minimal immune rejection after
transplantation into hundreds of millions of individuals of differing
sexes, ages and racial groups. This offers the potential to create the
first true stem cell bank, UniStemCell™, while avoiding the ethical
issue of using fertilized eggs. ISCO also produces and markets
specialized cells and growth media for therapeutic research worldwide
through its subsidiary Lifeline Cell Technology. More information is
available at ISCO's website, www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman 760-940-6383 kaldrich@intlstemcell.com or Brian
Lundstrom, President 760-640-6383 bl@intlstemcell.com or The
Investor Relations Group 212-825-3210 Media Relations: Laura
Colontrelle lcolontrelle@investorrelationsgroup.com or Investor
Relations: James Carbonara jcarbonara@investorrelationsgroup.com |